Cardio Diagnostics (CDIO) Competitors $4.37 -0.02 (-0.46%) Closing price 04:00 PM EasternExtended Trading$4.38 +0.01 (+0.34%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CDIO vs. ALVR, DARE, KLTO, RNTX, KZR, PASG, MIRA, ENLV, MBRX, and XCURShould you be buying Cardio Diagnostics stock or one of its competitors? The main competitors of Cardio Diagnostics include AlloVir (ALVR), Dare Bioscience (DARE), Klotho Neurosciences (KLTO), Rein Therapeutics (RNTX), Kezar Life Sciences (KZR), Passage Bio (PASG), MIRA Pharmaceuticals (MIRA), Enlivex Therapeutics (ENLV), Moleculin Biotech (MBRX), and Exicure (XCUR). These companies are all part of the "pharmaceutical products" industry. Cardio Diagnostics vs. Its Competitors AlloVir Dare Bioscience Klotho Neurosciences Rein Therapeutics Kezar Life Sciences Passage Bio MIRA Pharmaceuticals Enlivex Therapeutics Moleculin Biotech Exicure AlloVir (NASDAQ:ALVR) and Cardio Diagnostics (NASDAQ:CDIO) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, risk, media sentiment, profitability and valuation. Which has more volatility & risk, ALVR or CDIO? AlloVir has a beta of 0.63, meaning that its stock price is 37% less volatile than the S&P 500. Comparatively, Cardio Diagnostics has a beta of 2.91, meaning that its stock price is 191% more volatile than the S&P 500. Does the media prefer ALVR or CDIO? In the previous week, AlloVir and AlloVir both had 1 articles in the media. AlloVir's average media sentiment score of 0.00 beat Cardio Diagnostics' score of -0.50 indicating that AlloVir is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AlloVir 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cardio Diagnostics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Do analysts prefer ALVR or CDIO? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AlloVir 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Cardio Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Which has stronger valuation & earnings, ALVR or CDIO? Cardio Diagnostics has higher revenue and earnings than AlloVir. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlloVirN/AN/A-$190.42M-$20.23-0.40Cardio Diagnostics$40K192.28-$8.38MN/AN/A Is ALVR or CDIO more profitable? AlloVir has a net margin of 0.00% compared to Cardio Diagnostics' net margin of -30,465.10%. AlloVir's return on equity of -71.03% beat Cardio Diagnostics' return on equity.Company Net Margins Return on Equity Return on Assets AlloVirN/A -71.03% -61.27% Cardio Diagnostics -30,465.10%-72.78%-66.17% Do insiders and institutionals have more ownership in ALVR or CDIO? 66.1% of AlloVir shares are owned by institutional investors. Comparatively, 8.1% of Cardio Diagnostics shares are owned by institutional investors. 32.1% of AlloVir shares are owned by company insiders. Comparatively, 13.3% of Cardio Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. SummaryAlloVir beats Cardio Diagnostics on 6 of the 10 factors compared between the two stocks. Get Cardio Diagnostics News Delivered to You Automatically Sign up to receive the latest news and ratings for CDIO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CDIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CDIO vs. The Competition Export to ExcelMetricCardio DiagnosticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.69M$3.32B$6.10B$10.53BDividend YieldN/A2.29%5.51%4.67%P/E RatioN/A21.5485.6826.86Price / Sales192.28422.92582.47185.05Price / CashN/A46.3226.3031.10Price / Book0.6210.0613.246.72Net Income-$8.38M-$52.22M$3.30B$276.35M7 Day Performance8.98%5.85%4.67%3.10%1 Month Performance17.79%12.06%8.40%10.19%1 Year Performance-33.79%26.14%88.01%40.34% Cardio Diagnostics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CDIOCardio Diagnostics0.4938 of 5 stars$4.37-0.5%N/A-35.2%$7.69M$40K0.001Gap UpALVRAlloVirN/A$5.61+17.6%N/A-63.2%$28.29MN/A-0.28110High Trading VolumeDAREDare Bioscience1.9583 of 5 stars$2.09flat$10.00+378.5%-30.3%$28.17M$10K-0.9830News CoverageKLTOKlotho Neurosciences0.649 of 5 stars$0.51+11.3%N/AN/A$27.91MN/A-1.12N/AGap UpRNTXRein Therapeutics3.0819 of 5 stars$1.15-2.5%$10.00+769.6%N/A$27.50MN/A-0.439KZRKezar Life Sciences3.5462 of 5 stars$3.59-1.6%$9.00+150.7%-50.7%$26.73M$7M-0.3760PASGPassage Bio3.301 of 5 stars$8.14+1.8%$75.67+829.6%-38.9%$25.43MN/A-0.45130News CoverageMIRAMIRA Pharmaceuticals0.5573 of 5 stars$1.33+0.8%$17.00+1,178.2%+17.4%$25.17MN/A-2.712ENLVEnlivex Therapeutics2.2099 of 5 stars$1.01-1.9%$10.00+890.1%-28.0%$25.02MN/A-1.7470MBRXMoleculin Biotech3.0156 of 5 stars$0.49-1.0%$4.00+721.5%-79.6%$24.35MN/A0.0020Gap UpXCURExicure1.7554 of 5 stars$3.90+2.4%N/A+58.1%$24.07M$500K-1.0150News CoveragePositive NewsGap Down Related Companies and Tools Related Companies ALVR Competitors DARE Competitors KLTO Competitors RNTX Competitors KZR Competitors PASG Competitors MIRA Competitors ENLV Competitors MBRX Competitors XCUR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CDIO) was last updated on 10/7/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cardio Diagnostics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cardio Diagnostics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
